Introduction
============

Cholangiocarcinoma (CCA), comprising intrahepatic, perihilar and distal CCA, is an uncommon but lethal cancer type with increasing incidence and mortality worldwide; it is a malignancy that poses a great threat to human health and life ([@b1-ijo-55-01-0045],[@b2-ijo-55-01-0045]). In Asia, CCA has an even higher incidence and mortality compared with those in other regions due to higher prevalence of hepatitis B virus (HBV) infection and cirrhosis, as well as less advanced medical technology ([@b3-ijo-55-01-0045],[@b4-ijo-55-01-0045]). Although numerous improvements have been made during recent decades, including novel cancer markers, advanced surgical techniques and skills and novel targeted drugs, the prognosis of patients with CCA remains poor due to late diagnosis, high probability of peripheral vascular, liver and lymph node metastasis, and increased risk of recurrence ([@b5-ijo-55-01-0045]-[@b7-ijo-55-01-0045]). Thus, it is of critical importance to explore the molecular mechanisms associated with the pathogenesis of CCA, and to explore novel treatment targets for CCA to improve the prognosis of affected patients.

Long non-coding RNAs (lncRNAs), a group of endogenous RNAs of \>200 nucleotides in length with no protein-coding function, are implicated in numerous processes, including epigenetic gene expression regulation, gene imprinting, transcriptional activation, mRNA modification, nuclear transportation and protein activation ([@b8-ijo-55-01-0045],[@b9-ijo-55-01-0045]). Dysregulated lncRNA patterns have been observed to be implicated in the development of various cancers, and certain specific oncogenic or tumor suppressor lncRNAs have been discovered in numerous cancer types, which regulate cancer cell proliferation, apoptosis, migration, invasion and drug resistance via sponging target microRNAs (miRNAs) or binding with cancer-associated mRNAs ([@b10-ijo-55-01-0045]-[@b12-ijo-55-01-0045]). In particular, certain lncRNAs \[e.g. lnc-FEZ family zinc finger 1 (FEZF1)-antisense 1 (AS1) and lnc-THOR\] have been reported to regulate cancer cell stemness via affecting cancer stem cell (CSC) markers, including sex-determining region Y box 9 (SOX9), CD44 and Nanog homeobox (NANOG) ([@b13-ijo-55-01-0045]-[@b15-ijo-55-01-0045]). Since CSCs are considered to be the a crucial component of cancer metastasis and recurrence, two processes that are associated with poor prognosis ([@b16-ijo-55-01-0045],[@b17-ijo-55-01-0045]), these results indicate the potential of specific lncRNAs as treatment targets in cancer. As for CCA, limited data are available regarding the role of lncRNAs and only a small number of lncRNAs have been identified to be implicated in its pathogenesis. For instance, lncRNA EPIC1 was reported to promote CCA cell growth and colony formation while repressing apoptosis via regulating Myc ([@b18-ijo-55-01-0045]). Furthermore, lncRNA ArfGAP with SH3 domain, ankyrin repeat and PH domain 1-intronic transcript 1 was indicated to promote CCA cell proliferation, migration, invasion and epithelial-mesenchymal transition via the hedgehog signaling pathway ([@b19-ijo-55-01-0045]). In addition, lncRNA SOX2 overlapping transcript was reported to stimulate CCA cell proliferation and invasion, and to be associated with poor prognosis in CCA patients ([@b20-ijo-55-01-0045]). However, the functions of most lncRNAs in the pathogenesis of CCA remain largely elusive, and therefore further investigation is required.

The present study aimed to explore the lncRNA expression profiles in CCA by microarray analysis. The results of the microarray analysis identified lncRNA PKD2-2-3 (lnc-PKD2-2-3) as a key lncRNA in CCA. The aberrant expression of lnc-PKD2-2-3 in CCA compared with normal tissues was then confirmed by reverse transcription-quantitative polymerase chain reaction (RT-qPCR). The association of lnc-PKD2-2-3 with tumor features and patient prognosis was determined. Finally, the potential role of lnc-PKD2-2-3 in regulating stemness of CCA cells and its application as a CSC marker in CCA were assessed in *in vitro* experiments.

Materials and methods
=====================

Patients and samples
--------------------

A total of 60 consecutive CCA patients treated at the Second Affiliated Hospital of Harbin Medical University (Harbin, China) between January 2014 and December 2015 were enrolled in the present study. The tumor and paired adjacent tissues were obtained during the surgery and immediately stored in liquid nitrogen. The inclusion criteria were as follows: i) Diagnosis as primary CCA according to clinical and pathological findings; ii) age \>18 years; iii) the patient was scheduled for resection. Patients with prior neoadjuvant therapies were excluded. The present study was approved by the Ethics Committee of the Second Affiliated Hospital of Harbin Medical University (Harbin, China) and all patients provided written informed consent prior to enrollment.

The patients\' characteristics were recorded following enrollment and included the following: Age, sex, smoking status, drinking status, HBV infection status, Eastern Cooperative Oncology Group (ECOG) performance score, tumor site, tumor size, number of tumors, degree of tumor differentiation, tumor-nodes-metastasis (TNM) stage, carcinoembryonic antigen (CEA), carbohydrate antigen 199 (CA199) levels and surgery type. Furthermore, patients were followed up until the end of June 2018 with a median follow-up duration of 27.5 months, and the overall survival (OS) time was determined as the time of resection to the time of death.

Microarray and bioinformatics analyses
--------------------------------------

A total of 3 pairs of CCA tumor tissue and adjacent tissue were randomly selected from all samples and total RNA was extracted using TRIzol™ reagent (Invitrogen; Thermo Fisher Scientific, Inc.) followed by quantification using a NanoDrop-2000 (Thermo Fisher Scientific, Inc.) and integrity assessment using an Agilent Bioanalyzer 2100 (Agilent Technologies, Inc.). lncRNA and mRNA profiles were then detected using a lncRNA and mRNA microarray kit (Agilent Human lncRNA 4×180K microarray; Agilent Technologies, Inc.) according to the manufacturer\'s protocol. lncRNAs present in \>50% of samples were included in the bioinformatics analysis using R software (version 3.3.3). A volcano plot was drawn by dysregulated lncRNAs using the limma package with statistical significance defined as P\<0.05 and a fold change \>2.0. Heatmap analysis of dysregulated lncRNAs was performed using the Pheatmap package. Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analysis of dysregulated lncRNA were performed using the database for annotation, visualization and integrated discovery (DAVID) web server (<https://david.ncifcrf.gov>) ([@b21-ijo-55-01-0045],[@b22-ijo-55-01-0045]) based on correlated mRNA expression.

Validation of lnc-PKD2-2-3 expression by RT-qPCR
------------------------------------------------

lnc-PKD2-2-3 was one of the most upregulated lncRNAs according to the microarray detection. lnc-PKD2-2-3 targets were then identified by Pearson correlation coefficient, and enrichment analysis was performed using the target genes with DAVID (<https://david.ncifcrf.gov>) ([@b21-ijo-55-01-0045],[@b22-ijo-55-01-0045]). This bioinformatics analysis revealed that lnc-PKD2-2-3 was correlated with several oncogenes and stemness-associated genes. Thus, its expression was further assessed in 60 pairs of CCA tumor tissue and adjacent tissue by using RT-qPCR. Apart from the comparison of its expression between tumor tissue and adjacent tissue, the association of lnc-PKD2-2-3 with clinicopathological features as well as OS was analyzed.

Measurement of the correlation between lnc-PKD2-2-3 and CSC markers in CCA tissues
----------------------------------------------------------------------------------

In order to determine the association of lnc-PKD2-2-3 with tumor stemness, the expression levels of CSC markers CD44, CD133 and octamer-binding transcription factor 4 (OCT4) were detected in 60 CCA tumor tissues by RT-qPCR, and the correlation of lnc-PKD2-2-3 with CD44, CD133 and OCT4 levels was analyzed by Spearman analysis.

Cell sources and culture
------------------------

The human CCA cell line TFK-1 was purchased from the German Collection of Microorganisms and Cell Cultures GmbH (Braunschweig, Germany), while the human CCA cell line Huh-28 was purchased from the Japanese Cancer Research Bioresources Bank Cell Bank (Tokyo, Japan). TFK-1 cells were cultured in 90% RPMI-1640 medium (Gibco; Thermo Fisher Scientific, Inc.) and 10% fetal bovine serum (FBS; Gibco; Thermo Fisher Scientific, Inc.), while Huh-28 cells were cultured in 80% RPMI-1640 medium and 20% FBS. Cell culture was performed in a humidified atmosphere of 95% air and 5% CO~2~ at 37°C.

Lentivirus construction
-----------------------

Lentiviruses were constructed by Shanghai Gene Bio-Tech Co. In brief, shuttle plasmids for lnc-PKD2-2-3 overexpression and short hairpin (sh) RNA, as well as nonsense DNA fragment overexpression and nonsense DNA fragment shRNA negative control (NC) plasmids, were constructed using pLV1-CMV and pGLV-U6 plasmids, respectively, and then transferred into 293T cells along with envelope plasmids and package plasmids. Subsequently, the resulting lentivirus was obtained by collecting the cell supernatant at 48 and 72 h following transfection.

Lentivirus transfection
-----------------------

Control overexpression, lnc-PKD2-2-3 overexpression, control shRNA and lnc-PKD2-2-3 shRNA lentiviruses were transfected into TFK-1 and Huh-28 cells at a multiplicity of infection of 20 and cultured for 72 h. The cells in the different transfection groups were respectively named as the LV-NC group, LV-Lnc group, LVU6-NC group and LVU6-Lnc group. lnc-PKD2-2-3 expression was detected by RT-qPCR to determine transfection efficiency. The cells were then cultured with 8 *μ*g/ml puromycin (Sigma-Aldrich; Merck KGaA) for 9 days to obtain stably transfected TFK-1 and Huh-28 cells.

CSC marker expression and CD44^+^CD133^+^ cell proportion
---------------------------------------------------------

In order to explore the effect of lnc-PKD2-2-3 on regulating CCA stemness, expression levels of CSC markers CD44, CD133 and OCT4 were detected by qPCR and western blot analysis in each group at 72 h post-transduction. In addition, CD44^+^CD133^+^ cell proportions at 72 h were detected by flow cytometry using a FACSCalibur (BD Biosciences) and analyzed using Flowjo Software 7.6 (FlowJo, LLC). The antibodies used in flow cytometry were CD133 mouse monoclonal antibody (cat. no. 38725, flow-specific; Alexa Fluor^®^ 488-conjugated; Cell Signaling Technology, Inc.) and CD44 rat monoclonal antibody (cat. no. 80813; allophycocyanin-conjugated; Cell Signaling Technology, Inc.). In brief, cells were harvested, washed with PBS, resuspended in PBS/0.5% bovine serum albumin, then incubated with CD44 rat monoclonal antibody (dilution 1:160) and CD133 mouse monoclonal antibody (dilution 1:50) at room temperature for 1 h. Then the cells were collected, suspended in PBS and detected by flow cytometry.

Measurement of sphere formation efficiency
------------------------------------------

In order to validate the effect of lnc-PKD2-2-3 in regulating CCA stemness, sphere formation efficiency was detected in each group of transfected cells using a sphere formation assay. In brief, transfected CCA cells were cultured in Dulbecco\'s modified Eagle\'s/F12 medium supplemented with 2% B27 (both from Gibco; Thermo Fisher Scientific, Inc.), 20 ng/ml epidermal growth factor (Sigma-Aldrich; Merck KGaA), 20 ng/ml basic fibroblast growth factor (Gibco; Thermo Fisher Scientific, Inc.) and 4 *μ*g/ml heparin (Sigma-Aldrich; Merck KGaA) for 10 days, and the spheres with a diameter of \>50 *μ*m were counted under an inverted fluorescence microscope (Olympus) at ×200 magnification. The sphere formation efficiency was calculated as the number of these spheres divided by the total number of seeded cells.

Measurement of resistance to 5-fluorouracil (5-FU)
--------------------------------------------------

In order to further examine the effect of lnc-PKD2-2-3 in regulating CCA stemness, drug resistance of transduced CCA cells to 5-FU was investigated by measuring cell viability and apoptosis following 5-FU treatment. In brief, 200 ng/ml 5-FU was added in the medium of the transduced CCA cells, resulting into four treatments groups: LV-NC + 5-FU group, LV-Lnc + 5-FU group, LVU6-NC + 5-FU group and LVU6-Lnc + 5-FU group. After 24 h of incubation, the cell viability was measured using a Cell Counting Kit-8 (CCK-8; Sangon Biotech Co., Ltd.) according to the manufacturer\'s protocol with measurement of the absorbance under a microplate reader (BioTek Instruments, Inc.). The cell viability of LV-Lnc + 5-FU group was calculated relative to the LV-NC + 5-FU group, while the cell viability of LVU6-Lnc + 5-FU group was calculated relative to the LVU6-NC + 5-FU group. The cell apoptosis rate was measured using a fluorescein isothiocyanate Annexin V apoptosis detection kit II with a flow cytometer (both from BD Biosciences) according to the manufacturer\'s protocol and analyzed using Flowjo Software 7.6 (FlowJo, LLC). Furthermore, the expression of apoptotic markers \[cleaved caspase-3 (c-caspase-3) and B-cell lymphoma-2 (Bcl-2)\] were measured by western blot analysis.

Measurement of lnc-PKD2-2-3 expression in CCA stem-like cells
-------------------------------------------------------------

Drug-resistant TFK-1 and Huh-28 cells were generated using 5-FU (Sigma-Aldrich; Merck KGaA) with repeated treatment. In brief, cells were cultured in medium containing 200 ng/ml 5-FU for 72 h and in the second step, cultured in 5-FU-free medium for another 72 h. These processes were repeated until no effect of 5-FU on cell viability was observed by using the CCK-8 assay. The drug-resistant cell lines were referred to as R-TFK-1 and R-Huh-28. The sphere formation assay was then performed as aforementioned. Spheres were isolated by centrifugation to obtain samples referred to as S-TFK-1 and S-Huh-28, which served as CCA stem-like cells that were validated by measurement of CSC marker expression CD44, CD133 and OCT4, using RT-qPCR and western blotting, with parental normal CCA cells (TFK-1 and Huh-28) as a reference. Finally, lnc-PKD2-2-3 expression in CCA stem-like cells (S-TFK-1 and S-Huh-28) and normal CCA cells (TFK-1 and Huh-28) was measured using RT-qPCR.

RT-qPCR
-------

After extraction of total RNA by TRIzol™ reagent (Invitrogen; Thermo Fisher Scientific, Inc.) from tissues or cells, quality control was performed with a NanoDrop-2000 (Thermo Fisher Scientific, Inc.) and Agilent Bioanalyzer 2100 (Agilent Technologies, Inc.). The RNA was reverse transcribed into complementary DNA using a PrimeScript™ RT reagent kit (Perfect Real Time; Takara Bio Inc.) and qPCR was performed using SYBR^®^ Green Real-time PCR master mix (Toyobo Life Science). The thermocycling conditions were as follows: 95°C for 5 min, then 40 cycles of 94°C for 30 sec, 61°C for 30 sec. Relative fold changes in mRNA expression were calculated using the formula 2^-ΔΔCq^ ([@b23-ijo-55-01-0045]) with GAPDH serving as the internal reference. The sequences of the primers are provided in [Table I](#tI-ijo-55-01-0045){ref-type="table"}.

Western blot analysis
---------------------

Total protein was extracted using radioimmunoprecipitation assay lysis buffer (Thermo Fisher Scientific, Inc.) and the protein concentration was measured and adjusted with a bicinchoninic acid kit for protein determination (Sigma-Aldrich; Merck KGaA). A total of 20 *μ*g protein per lane was then separated using 10% Bis-Tris protein gels (Invitrogen; Thermo Fisher Scientific, Inc.), followed by transfer onto a polyvinylidene fluoride membrane (EMD Millipore). Subsequently, the membrane was blocked in 5% skimmed milk at 37°C for 90 min, and then incubated with primary antibody at 4°C overnight, followed by incubation with secondary antibody at room temperature for 1 h. Finally, visualization of blots was performed using highly sensitive enhanced chemiluminescence reagent (Sangon Biotech Co., Ltd.) and exposed to X-ray films. GAPDH was used as an internal reference. The antibodies are listed in [Table II](#tII-ijo-55-01-0045){ref-type="table"}.

Statistical analysis
--------------------

Statistical analysis was performed using SPSS 22.0 Software (IBM Corporation) and GraphPad Prism software 6.01 (GraphPad Inc.). Values are expressed as the mean ± standard deviation or median (25th-75th value). Comparison of paired data between two groups was performed using a Wilcoxon signed rank-sum test. Comparison of individual data between two groups was performed using a t-test or Wilcoxon rank-sum test. Correlations were determined using Spearman analysis. OS between two groups was compared using Kaplan-Meier curves and the log-rank test. P\<0.05 was considered to indicate statistical significance.

Results
=======

Dysregulated lncRNA profiles in CCA determined by micro- array analysis
-----------------------------------------------------------------------

A total of 46,846 lncRNAs were detected in \>50% samples and included in the analysis, among which 4,223 were upregulated and 4,596 were downregulated in CCA tumor tissues compared with paired adjacent tissues ([Fig. 1A](#f1-ijo-55-01-0045){ref-type="fig"}). The top 10 upregulated and top 10 downregulated lncRNAs are listed in [Table SI](#SD1-ijo-55-01-0045){ref-type="supplementary-material"}. Heatmap analysis revealed that these up and downregulated lncRNAs were able to distinguish CCA tumor tissue from paired adjacent tissue ([Fig. 1B](#f1-ijo-55-01-0045){ref-type="fig"}). GO enrichment analysis indicated that dysregulated lncRNAs were enriched in GO terms in the categories molecular mechanism (including calcium-dependent protein binding, cell adhesive protein binding and nitric oxide binding), cellular component \[including extracellular exosome, cell surface and extracellular matrix (ECM)\] and biological process (including complement activation, lectin pathway, ECM organization and cell adhesion; [Fig. 1C](#f1-ijo-55-01-0045){ref-type="fig"}). KEGG enrichment analysis revealed that the dysregulated lncRNAs were enriched in pathways involving ECM-receptor interaction, alcoholism, PI3K/Akt signaling and pathways in cancer ([Fig. 1D](#f1-ijo-55-01-0045){ref-type="fig"}). These results indicated that the identified dysregulated lncRNAs may have critical roles in CCA.

A ssociation of lnc-PK D2-2-3 expression with clinicopathological features and prognosis in CCA patients
--------------------------------------------------------------------------------------------------------

lnc-PKD2-2-3 was one of the most upregulated lncRNAs in the microarray data ([Table SI](#SD1-ijo-55-01-0045){ref-type="supplementary-material"}). In addition, bioinformatics results, using Pearson correlation coefficient and DAVID ([@b21-ijo-55-01-0045],[@b22-ijo-55-01-0045]) analyses, revealed that lnc-PKD2-2-3 was correlated with several oncogenes and stemness-associated pathways, including DGAT2, GPAM, HEPACAM, ATP1A1, PAFAH1B3, LOC728342, STAB2, SH2D3A and GTF2I. Therefore, its expression was further validated in 60 pairs of CCA tumor tissue and adjacent tissue by RT-qPCR. The results indicated that lnc-PKD2-2-3 levels were significantly increased in CCA tumor tissue compared with paired adjacent tissue ([Fig. 2A](#f2-ijo-55-01-0045){ref-type="fig"}). In addition, lnc-PKD2-2-3 levels were significantly associated with a higher ECOG performance score, poor differentiation, increased TNM stage and abnormal CEA levels, while it was not associated with age, sex, smoking, drinking, HBV infection, tumor site, tumor size, number of tumors, CA199 levels or surgery type ([Table III](#tIII-ijo-55-01-0045){ref-type="table"}).

All patients were followed up and 54 cases died, among which 48 (89%) died due to tumor progression, 2 died from infection, 2 died from cardiovascular and cerebrovascular diseases and 2 died from other causes. The patients were divided into lnc-PKD2-2-3-high expression and lnc-PKD2-2-3-low expression groups, according to the median value of lnc-PKD2-2-3 levels in the tumor tissues. Survival analysis revealed that high expression of lnc-PKD2-2-3 was associated with a worse OS compared with subjects with low expression ([Fig. 2B](#f2-ijo-55-01-0045){ref-type="fig"}).

Correlation of lnc-PKD2-2-3 expression with CSC marker expression in CCA tissue
-------------------------------------------------------------------------------

The expression of common CSC markers in the CCA tumor tissues was then measured, and it was revealed that lnc-PKD2-2-3 expression was positively correlated with CD44 ([Fig. 3A](#f3-ijo-55-01-0045){ref-type="fig"}), CD133 ([Fig. 3B](#f3-ijo-55-01-0045){ref-type="fig"}) and OCT4 ([Fig. 3C](#f3-ijo-55-01-0045){ref-type="fig"}) expression. These results implied that lnc-PKD2-2-3 expression may correlate with CCA stemness and may have the potential to serve as a CSC marker.

lnc-PKD2-2-3 expression of CCA cell lines post-transduction
-----------------------------------------------------------

lnc-PKD2-2-3 expression was increased in the overexpressing LV-Lnc group compared with the LV-NC group, while it was decreased in the silencing LVU6-Lnc group compared with the LVU6-NC group, following transduction with the respective lentivirus in TFK-1 cells ([Fig. 4A](#f4-ijo-55-01-0045){ref-type="fig"}) and Huh-28 cells ([Fig. 4B](#f4-ijo-55-01-0045){ref-type="fig"}). These results indicated that the expression of lnc-PKD2-2-3 was successfully upregulated or suppressed by the overexpressing or the silencing lentivirus, respectively.

lnc-PKD2-2-3 increases CSC marker expression and CD44^+^CD133^+^ cell proportion in CCA cell lines
--------------------------------------------------------------------------------------------------

The mRNA expression levels of CD44, CD133 and OCT4 were elevated in the LV-Lnc group compared with the LV-NC group, while it was reduced in the LVU6-Lnc group compared with the LVU6-NC group, in TFK-1 cells ([Fig. 5A-C](#f5-ijo-55-01-0045){ref-type="fig"}) and Huh-28 cells ([Fig. 5G-I](#f5-ijo-55-01-0045){ref-type="fig"}). The protein expression levels of these markers were also increased in the LV-Lnc group compared with the LV-NC group, and reduced in the LVU6-Lnc group compared with the LVU6-NC group, in TFK-1 cells ([Fig. 5D](#f5-ijo-55-01-0045){ref-type="fig"}) and Huh-28 cells ([Fig. 5J](#f5-ijo-55-01-0045){ref-type="fig"}). Notably, the CD44^+^CD133^+^ cell proportion was increased in the LV-Lnc group compared with the LV-NC group, and decreased in the LVU6-Lnc group compared with the LVU6-NC group, in TFK-1 cells ([Fig. 5E and F](#f5-ijo-55-01-0045){ref-type="fig"}) and Huh-28 cells ([Fig. 5K and L](#f5-ijo-55-01-0045){ref-type="fig"}). These results implied that lnc-PKD2-2-3 overexpression may increase CCA stemness.

lnc-PKD2-2-3 enhances sphere formation efficiency in CCA cell lines
-------------------------------------------------------------------

The sphere formation assay revealed that the sphere formation efficiency was increased in the LV-Lnc group compared with the LV-NC group, while it was reduced in the LVU6-Lnc group compared with the LVU6-NC group, in TFK-1 cells ([Fig. 6A and B](#f6-ijo-55-01-0045){ref-type="fig"}) and in Huh-28 cells ([Fig. 6C and D](#f6-ijo-55-01-0045){ref-type="fig"}). These results further suggested that lnc-PKD2-2-3 overexpression increased CCA stemness.

lnc-PKD2-2-3 increases drug resistance to 5-FU in CCA cell lines
----------------------------------------------------------------

Following 5-FU treatment, the viability of TFK-1 cells in the LV-Lnc + 5-FU group was increased compared with the LV-NC + 5-FU group, while the viability in the LVU6-Lnc + 5-FU group was decreased compared with the LVU6-NC + 5-FU group ([Fig. 7A](#f7-ijo-55-01-0045){ref-type="fig"}). By contrast, the apoptotic rate of TFK-1 cells was repressed in the LV-Lnc + 5-FU group compared with the LV-NC + 5-FU group, while it was enhanced in the LVU6-Lnc + 5-FU group compared with the LVU6-NC + 5-FU group ([Fig. 7B and D](#f7-ijo-55-01-0045){ref-type="fig"}). Furthermore, in TFK-1 cells, the apoptotic marker C-caspase-3 was decreased in the LV-Lnc + 5-FU group compared with the LV-NC + 5-FU group, while it was increased in the LVU6-Lnc + 5-FU group compared with the LVU6-NC + 5-FU group ([Fig. 7C](#f7-ijo-55-01-0045){ref-type="fig"}). The opposite trend was observed for the anti-apoptotic marker Bcl-2 ([Fig. 7C](#f7-ijo-55-01-0045){ref-type="fig"}). Similar to the TFK-1 cell lines, experiments in the Huh-28 cell line also indicated that the cell viability was enhanced ([Fig. 7E](#f7-ijo-55-01-0045){ref-type="fig"}), while cell apoptosis was inhibited ([Fig. 7F-H](#f7-ijo-55-01-0045){ref-type="fig"}) by lnc-PKD2-2-3 in the presence of 5-FU treatment. These results demonstrated that lnc-PKD2-2-3 overexpression increased drug resistance to 5-FU in CCA cell lines, which further suggested that lnc-PKD2-2-3 may have the potential to increase CCA stemness.

lnc-PKD2-2-3 levels are increased in CCA stem-like cells

CCA stem-like cells were obtained by generation of 5-FU-resistant CCA cells (termed R-TFK-1 and R-Huh-28), that were further selected in a sphere formation assay, followed by isolation through centrifugation. Cell viability was similar between the R-TFK-1 cells treated with 5-FU and the untreated R-TFK-1 cells ([Fig. 8A](#f8-ijo-55-01-0045){ref-type="fig"}), as well as between the R-Huh-28 cells treated with 5-FU and the untreated R-Huh-28 cells ([Fig. 8D](#f8-ijo-55-01-0045){ref-type="fig"}), confirming that the generated R-TFK-1 and R-Huh-28 cells were resistant to 5-FU. Of note, R-TFK-1 cells exhibited increased sphere formation efficiency compared with parental TFK-1 cells ([Fig. 8B](#f8-ijo-55-01-0045){ref-type="fig"}); a representative sphere is displayed in [Fig. 8C](#f8-ijo-55-01-0045){ref-type="fig"}. R-Huh-28 cells also exhibited increased sphere formation efficiency compared with the parental Huh-28 cells ([Fig. 8E](#f8-ijo-55-01-0045){ref-type="fig"}); a representative sphere is displayed in [Fig. 8F](#f8-ijo-55-01-0045){ref-type="fig"}.

Subsequently, CD44, CD133 and OCT4 expression was measured in spheres of TFK-1 cells (S-TFK-1) and parental TFK-1 cells, as well as in spheres of Huh-28 cells (S-Huh-28) and parental Huh-28 cells. The results revealed that mRNA and protein expression levels of CD44, CD133 and OCT4 were increased in S-TFK-1 cells compared with parental TFK-1 cells ([Fig. 9A-D](#f9-ijo-55-01-0045){ref-type="fig"}), and in S-Huh-28 cells compared with parental Huh-28 cells ([Fig. 9F-I](#f9-ijo-55-01-0045){ref-type="fig"}). These results implied the successful generation of CCA stem-like cells by sphere isolation (S-TFK-1 and S-Huh-28 groups). Finally, lnc-PKD2-2-3 expression was demonstrated to be significantly increased in S-TFK-1 cells compared with parental TFK-1 cells ([Fig. 9E](#f9-ijo-55-01-0045){ref-type="fig"}), and in S-Huh-28 cells compared with parental Huh-28 cells ([Fig. 9J](#f9-ijo-55-01-0045){ref-type="fig"}). These results further indicated that lnc-PKD2-2-3 may serve as a novel marker for CSCs in CCA.

Discussion
==========

In the present study, lncRNA expression profiles in CCA were first obtained by microarray analysis, which provided 4,223 upregulated and 4,596 downregulated lncRNAs in CCA tumor tissues compared with paired adjacent tissues. These dysregulated lncRNAs were identified to be enriched in various cancer-associated pathways. Furthermore, lnc-PKD2-2-3, one of the most upregulated lncRNAs identified in the microarray analysis, was confirmed to be upregulated in CAA tissues. High lnc-PKD2-2-3 expression was determined to be associated with a higher ECOG performance score, poor differentiation, advanced TNM stage and increased CEA, and was a predictor of poor prognosis in CCA patients. Of note, it was also revealed that overexpression of lnc-PKD2-2-3 in CCA cell lines significantly increased CSC marker expression (CD44, CD133 and OCT4) and CD44^+^CD133^+^ cell proportion, enhanced sphere formation efficiency and increased drug resistance to 5-FU, indicating that lnc-PKD2-2-3 may promote CCA stemness. In addition, lnc-PKD2-2-3 was positively correlated with CSC markers in CCA tumor tissues and was markedly upregulated in CCA stem-like cells compared with normal CCA cells, suggesting that lnc-PKD2-2-3 may potentially serve as a marker for CSCs in CCA.

lncRNAs, as a group of newly discovered non-coding RNAs, participate in various molecular biological processes, and their differential expression patterns have been implicated in the pathogenesis of numerous diseases, including vascular disease, diabetes and various types of cancer ([@b24-ijo-55-01-0045]-[@b26-ijo-55-01-0045]). A previous study identified 10,680 dysregulated lncRNAs in colorectal cancer tissues compared with paired adjacent normal tissues by microarray analysis, and 2,970 lncRNAs were differentially expressed in tumor tissues with liver metastasis compared with tumor tissues without liver metastasis, indicating that lncRNA profiles are involved in carcinogenesis and metastasis of colorectal cancer ([@b27-ijo-55-01-0045]). Another two studies reported 214 dysregulated lncRNAs in hepatocellular carcinoma tissues compared with paired adjacent tissues by high-throughput RNA sequencing and 234 aberrant lncRNAs were identified in the blood of hepatocellular carcinoma patients with vs. without lymph node metastasis ([@b28-ijo-55-01-0045],[@b29-ijo-55-01-0045]). As for CCA, only one previous original study explored the lncRNA expression patterns between extrahepatic CCA tissue and normal non-cancerous tissue using microarray, and it only used a limited set of probes for lncRNA detection; thus, only 268 dysregulated lncRNAs were identified and most aberrant lncRNAs remained undetected ([@b30-ijo-55-01-0045]). In the present study, \>80,000 probes were designed in a microarray and a total of 46,846 lncRNAs were detected in \>50% of samples of CCA tumor tissue and adjacent tissue, which were included in the bioinformatics analysis. A total of 4,223 upregulated lncRNAs and 4,596 downregulated lncRNAs were identified in CCA tumor tissues compared with paired adjacent tissues, and these dysregulated lncRNAs were enriched in cancer-associated pathways, including ECM-receptor interaction, alcoholism and PI3K/Akt signaling. These results indicated that dysregulated lncRNA profiles may have critical roles in CCA carcinogenesis.

lncRNAs have also been reported to serve as markers of tumor development, progression and prognosis in numerous types of cancer. For instance, lncRNA TP73-AS1 was reported to be upregulated in tumor tissue and to be associated with larger tumor size, TNM stage and shorter OS in gastric cancer patients ([@b31-ijo-55-01-0045]). lncRNA serine peptidase inhibitor, Kunitz type 1-AS1 was determined to be overexpressed in cancer tissue and to be associated with a higher risk of regional lymph node metastasis and distant metastasis, and it is also an independent predictor of shorter relapse-free survival in colorectal cancer patients ([@b32-ijo-55-01-0045]). In addition, upregulated lncRNA gastric carcinoma proliferation enhancing transcript 1 was reported to be associated with vascular invasion, cirrhosis, tumor size and Edmondson-Steiner grade, and is a predictor of poor survival ([@b33-ijo-55-01-0045]). In the present study, since lnc-PKD2-2-3 was one of the most upregulated lncRNAs detected by microarray, and bioinformatics analysis revealed that it was associated with several oncogenes and stemness-associated genes, its expression was further validated in 60 pairs of CCA tumor tissue and adjacent tissue using RT-qPCR. It was observed that lnc-PKD2-2-3 was upregulated and associated with a higher ECOG performance score, poor differentiation, advanced TNM stage and increased CEA, as well as associated with poor prognosis in CCA patients.

Of note, the present study was the first to report on the function of lnc-PKD2-2-3 in carcinogenesis. The roles of lnc-PKD2-2-3 in cancer may be based on the following mechanisms: i) lnc-PKD2-2-3 promotes CCA stemness and then stimulates tumor progression and enhances drug resistance, thus leading to tumor progression and poor prognosis, which was validated in the *in vitro* experiments of the present study; ii) lnc-PKD2-2-3 may increase CCA progression via sponging tumor suppressive target miRNAs or enhancing the function of oncogenes or cancer-associated pathways, thus giving rise to advanced tumor features and unfavorable prognosis. The latter hypothesis requires further investigation. The results of the present study indicated that lnc-PKD2-2-3 may serve as a marker of tumor development, progression and prognosis in CCA.

CSCs, a concept first put forward a decade ago and initially proposed in acute myeloid leukemia, are a small population of stem-like cancer cells exhibiting the capacity of self-renewal and differentiation into various types of cancer cells, which are considered to have a crucial role in increasing drug resistance and disease relapse in various types of cancer ([@b34-ijo-55-01-0045],[@b35-ijo-55-01-0045]). In experimental models, cytotoxic agents have been demonstrated to lack efficacy in killing CSCs, and CSCs are also reported to be responsible for the metastasis and re-growth of tumors after unsuccessful treatment ([@b34-ijo-55-01-0045],[@b35-ijo-55-01-0045]). Thus, deeper investigation of underlying mechanisms and additional targets/markers of CSCs are of critical importance for developing treatments for cancer, including CCA. Recently, a small number of unique lncRNAs have been observed to participate in the regulation of cancer-cell stemness and to have potential as markers for CSCs in several cancer types. For instance, lnc-THOR was reported to increase gastric cancer cell stemness by upregulating CSC marker expression and the capacity of spheroid formation of cells via enhancing the stability of SOX9 mRNA ([@b13-ijo-55-01-0045]). lncRNA transcription factor 7 has been reported to induce CSC self-renewal (detected by CSC marker expression and spheroid formation efficiency) and tumor propagation via regulation of Wnt signaling pathways ([@b14-ijo-55-01-0045]). Furthermore, inhibition of lncRNA FEZF1-AS1 was demonstrated to decrease breast cancer stem cell stemness by measurement of CSC marker expression and determination of the mammosphere-forming ability, through targeting the miR-30a and NANOG axis ([@b15-ijo-55-01-0045]). As for CCA, no previous study has reported on the role of lncRNAs in stemness regulation. To the best of our knowledge, the present study is the first to report that lnc-PKD2-2-3 increased CSC marker expression and CD44^+^CD133^+^ cell proportion, improved the sphere formation efficiency and enhanced drug resistance to 5-FU in CCA cell lines, indicating that lnc-PKD2-2-3 may promote CCA stemness. Furthermore, lnc-PKD2-2-3 was positively correlated with CSC markers in CCA tumor tissues and was markedly upregulated in CCA stem-like cells compared with normal CCA cells, implying that lnc-PKD2-2-3 may potentially serve as a marker for CSCs in CCA. Notably, the CD133 expression in the control group of TFK-1 and Huh-28 was numerically higher than that reported in a previous study ([@b36-ijo-55-01-0045]), while it was similar compared with that in other previous studies ([@b37-ijo-55-01-0045],[@b38-ijo-55-01-0045]); this discrepancy may result from different detection methods, exposure time of western blot, dilution of antibody and experimental conditions among the different studies. Considering the aforementioned data, the present findings would provide novel evidence for application of lncRNA as a target to eliminate CSCs, and to further decrease treatment refraction and disease relapse in CCA.

In conclusion, lnc-PKD2-2-3, identified from lncRNA expression profiling, was associated with pejorative tumor features and poor prognosis, and may serve as a CSC marker that is associated with CD44, CD133 and OCT4 expression, and CD44^+^CD133^+^ cell proportion. In addition, lnc-PKD2-2-3 overexpression increased sphere formation efficiency and enhanced drug resistance to 5-FU in CCA cell lines. The present study provided novel evidence for the application of a lncRNA as a target to eliminate CSCs and to reverse drug resistance and disease relapse in patients with CCA.
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![Bioinformatics analysis of microarray. (A) Volcano plot. Red spots indicate upregulated lncRNAs, green spots indicate unchanged lncRNAs, and blue spots indicate downregulated lncRNAs. (B) Heatmap analysis of dysregulated lncRNAs. (C) GO enrichment analysis of dysregulated lncRNAs. (D) KEGG enrichment analysis of dysregulated lncRNAs. lncRNA, long non-coding RNA; GO, Gene Ontology; KEGG, Kyoto Encyclopedia of Genes and Genomes; DEG, differentially expressed gene.](IJO-55-01-0045-g00){#f1-ijo-55-01-0045}

![Correlation of lnc-PKD2-2-3 expression with prognosis. (A) Lnc-PKD2-2-3 levels were detected in CCA tumor tissues and in paired normal adjacent tissues. (B) Survival analysis of patients with high or low lnc-PKD2-2-3 expression. Comparison of expression was determined by Wilcoxon signed rank sum test. Survival analysis was performed with Kaplan-Meier curve followed by log-rank test. CCA, cholangiocarcinoma; OS, overall survival.](IJO-55-01-0045-g01){#f2-ijo-55-01-0045}

![Correlation of lnc-PKD2-2-3 with CSC marker expression. Lnc-PKD2-2-3 expression was positively associated with (A) CD44, (B) CD133 and (C) OCT4 expression in cholangiocarcinoma tumor tissues. Correlation was determined by Spearman test. CSC, cancer stem cell; OCT4, octamer-binding transcription factor 4.](IJO-55-01-0045-g02){#f3-ijo-55-01-0045}

![Lnc-PKD2-2-3 expression following lentivirus transduction. (A) TFK-1 cells and (B) Huh-28 cells were transduced with either lnc-PKD2-2-3-over-expressing lentivirus (LV-Lnc) and control (LV-NC), or with lnc-PKD2-2-3-silencing lentivirus (LVU6-Lnc) and control (LVU6-NC). ^\*\*\*^P\<0.001, with comparisons indicated by brackets. NC, negative control.](IJO-55-01-0045-g03){#f4-ijo-55-01-0045}

###### 

CSC marker expression and CD44^+^CD133^+^ cell proportion following lentivirus transduction. (A) mRNA expression levels of CD44, (B) CD133 and (C) OCT4 in TFK-1 experimental cell groups. (D) Representative western blot of CSC marker expression in TFK-1 experimental cell groups. (E) Quantification and (F) representative plots of flow cytometry analysis for CD44^+^CD133^+^ proportions in TFK-1 experimental cell groups. (G) mRNA expression levels of CD44, (H) CD133 and (I) OCT4 in Huh-28 experimental cell groups. (J) Representative western blot of CSC marker expression in Huh-28 experimental cell groups. (K) Quantification and (L) representative plots of flow cytometry analysis for CD44^+^CD133^+^ proportions in Huh-28 experimental cell groups. ^\*^P\<0.05, ^\*\*^P\<0.01 and ^\*\*\*^P\<0.001, with comparisons indicated by brackets. CSC, cancer stem cell; NC, negative control.
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![Sphere formation efficiency following lentivirus transduction. (A) Quantification and (B) representative microscopy image (magnification, ×200) from sphere formation assay in TFK-1 experimental cell groups. (C) Quantification and (D) representative microscopy image (magnification, ×200) from sphere formation assay in Huh-28 experimental cell groups. ^\*^P\<0.05 and ^\*\*^P\<0.01, with comparisons indicated by brackets. NC, negative control.](IJO-55-01-0045-g06){#f6-ijo-55-01-0045}

![Drug resistance to 5-FU following lentivirus transduction. (A) Cell viability was measured in TFK-1 experimental cell groups by CCK-8 assay. (B) Cell apoptosis was measured in TFK-1 experimental cell groups by flow cytometry analysis. (C) Expression of apoptosis-related proteins was evaluated in TFK-1 experimental cell groups by western blotting. (D) Representative plots from flow cytometry analysis in panel B. (E) Cell viability was measured in Huh-28 experimental cell groups by CCK-8 assay. (F) Cell apoptosis was measured in Huh-28 experimental cell groups by flow cytometry analysis. (G) Expression of apoptosis-related proteins was evaluated in Huh-28 experimental cell groups by western blotting. (H) Representative plots from flow cytometry analysis in panel F. ^\*^P\<0.05 and ^\*\*^P\<0.01, with comparisons indicated by brackets. 5-FU, 5-fluorouracil; CCK-8, cell counting kit-8; NC, negative control; Bcl-2, B-cell lymphoma-2; PI, propidium iodide; AV, Annexin V.](IJO-55-01-0045-g07){#f7-ijo-55-01-0045}

![Generation of CCA stem-like cells. CCA stem-like cells were constructed by 5-FU repeated treatment, sphere formation assay and sphere isolation. (A) Drug resistant R-TFK-1 cells were constructed and confirmed to have equal cell viability with or without 5-FU treatment. (B) Quantification and (C) representative image (magnification, ×200) of sphere formation assay in R-TFK-1 and TFK-1 cells. (D) Similarly, drug resistant R-Huh-28 cells were constructed and confirmed to have equal cell viability with or without 5-FU treatment. (E) Quantification and (F) representative image (magnification, ×200) of sphere formation assay in R-Huh-28 and Huh-28 cells. ^\*\*\*^P\<0.001, with comparisons indicated by brackets. CCA, cholangiocarcinoma; 5-FU, 5-fluorouracil; R, resistant; NS, not significant.](IJO-55-01-0045-g08){#f8-ijo-55-01-0045}

![Validation of cholangiocarcinoma stem-like cells and lnc-PKD2-2-3 expression. (A) mRNA levels of CD44, (B) CD133 and (C) OCT4, as well as (D) their protein levels were measured in the S-TFK-1 and parental TFK-1 cells. (E) Lnc-PKD2-2-3 levels in the S-TFK-1 and parental TFK-1 cells. (F) mRNA levels of CD44, (G) CD133 and (H) OCT4, as well as (I) their protein levels were measured in the S-Huh-28 and parental Huh-28 cells. (J) Lnc-PKD2-2-3 levels in the S-Huh-28and parental Huh-28 cells. ^\*\*^P\<0.01 and ^\*\*\*^P\<0.001, with comparisons indicated by brackets. S, stem-like; OCT4, octamer-binding transcription factor 4.](IJO-55-01-0045-g09){#f9-ijo-55-01-0045}

###### 

Primers used for quantitative PCR.

  Gene           Forward Primer (5′-3′)     Reverse Primer (5′-3′)
  -------------- -------------------------- ---------------------------
  lnc-PKD2-2-3   AGGCTGATTCTGGAAGTTCTGAG    AGGAGATTCTGCTTCTGAGATGG
  CD44           ACATCCTCACATCCAACACCTC     CCTCCTGAAGTGCTGCTCCT
  CD133          GCTGCTTGTGGAATAGACAGAATG   GAAGGACTCGTTGCTGGTGAAT
  OCT4           AAGCGATCAAGCAGCGACTA       CAGAGTGGTGACGGAGACAG
  GAPDH          GAGTCCACTGGCGTCTTCAC       ATCTTGAGGCTGTTGTCATACTTCT

lnc-PKD22-2-3, long non-coding RNA PKD2-2-3; OCT4, octamer-binding transcription factor 4.

###### 

Antibodies used for western blotting.

  Antibody                                               Company   Catalog no.   Dilution
  ------------------------------------------------------ --------- ------------- ----------
  Primary                                                                        
  Rabbit polyclonal to caspase-3                         Abcam     ab90437       1:2,000
  Rabbit polyclonal to cleaved caspase-3                 Abcam     ab49822       1:2,000
  Rabbit polyclonal to Bcl-2                             Abcam     ab194583      1:2,000
  Rabbit polyclonal to CD44                              Abcam     ab157107      1:2,000
  Rabbit polyclonal to CD133                             Abcam     ab19898       1:2,000
  Rabbit polyclonal to OCT4                              Abcam     ab19857       1:2,000
  Rabbit monoclonal to GAPDH                             Abcam     ab9485        1:2,000
  Secondary                                                                      
  Goat anti-rabbit (horseradish peroxidase-conjugated)   Abcam     ab6721        1:4,000

Bcl-2, B-cell lymphoma-2; OCT4, octamer-binding transcription factor 4.

###### 

Patient characteristics.

  Parameters                      CCA patients (n=60)   lnc-PKD2-2-3 expression   P-value
  ------------------------------- --------------------- ------------------------- ---------
  Age, n (%)                                                                      0.412
   ≥60 years                      26 (43.3)             2.449 (1.629-3.829)       
   \<60 years                     34 (56.7)             2.888 (1.803-4.624)       
  Sex, n (%)                                                                      0.358
   Male                           42 (70.0)             2.760 (1.911-4.624)       
   Female                         18 (30.0)             2.495 (1.595-3.809)       
  Smoke, n (%)                                                                    0.404
   Yes                            19 (31.7)             3.371 (1.836-4.060)       
   No                             41 (68.3)             2.600 (1.642-4.602)       
  Drink, n (%)                                                                    0.663
   Yes                            29 (48.3)             2.636 (1.642-4.160)       
   No                             31 (51.7)             2.887 (1.751-4.739)       
  HBV infection, n (%)                                                            0.094
   Yes                            24 (40.0)             2.981 (2.310-4.631)       
   No                             36 (60.0)             2.449 (1.501-4.414)       
  ECOG performance score, n (%)                                                   0.005
   1-2                            24 (40.0)             4.121 (2.535-6.313)       
   0                              36 (60.0)             2.348 (1.579-3.272)       
  Differentiation, n (%)                                                          0.002
   Poor                           26 (43.3)             3.244 (2.598-5.924)       
   Well and moderate              34 (56.7)             2.180 (1.459-3.757)       
  Tumor site, n (%)                                                               0.874
   Intrahepatic                   18 (30.0)             2.563 (1.609-4.230)       
   Perihilar                      21 (35.0)             2.887 (1.895-4.525)       
   Extrahepatic                   21 (35.0)             2.864 (1.667-4.530)       
  Tumor size, n (%)                                                               0.052
   ≥5 cm                          27 (45.0)             3.678 (1.836-5.337)       
   \<5 cm                         33 (55.0)             2.517 (1.677-3.409)       
  Tumor number, n (%)                                                             0.172
   Multiple                       20 (33.3)             3.378 (1.799-5.646)       
   Single                         40 (66.7)             2.563 (1.714-3.732)       
  T stage, n (%)                                                                  0.051
   T3/T4                          17 (28.3)             3.750 (2.445-6.686)       
   T1/T2                          43 (71.7)             2.600 (1.633-3.987)       
  N stage, n (%)                                                                  0.002
   N1                             23 (38.3)             4.465 (2.657-6.471)       
   N0                             37 (61.7)             2.324 (1.597-3.176)       
  TNM stage, n (%)                                                                0.004
   III/IV                         25 (41.7)             3.777 (2.553-6.154)       
   I/II                           35 (58.3)             2.324 (1.562-3.371)       
  CEA abnormal, n (%)                                                             0.024
   Yes (≥5 ng/ml)                 23 (38.3)             3.050 (2.237-5.712)       
   No (\<5 ng/ml)                 37 (61.7)             2.282 (1.597-3.770)       
  CA199 abnormal, n (%)                                                           0.452
   Yes (≥37 U/ml)                 32 (53.3)             3.447 (1.633-5.073)       
   No (\<37 U/ml)                 28 (46.7)             2.589 (1.794-4.019)       
  Surgery, n (%)                                                                  0.207
   LR                             17 (28.3)             2.982 (2.558-4.441)       
   BT                             34 (56.7)             2.306 (1.593-4.055)       
   WR                             9 (15.0)              3.117 (1.840-5.772)       

CCA, cholangiocarcinoma; lnc-PDK2-2-3, long non-coding RNA PKD2-2-3; HBV, hepatitis B virus; ECOG, Eastern Cooperative Oncology Group; CEA, carcinoembryonic antigen; CA199, carbohydrate antigen199; LR, liver resection; BT, biliary duct resection; WR, Whipple resection.
